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Increasing data suggests and supports the idea that the gut microbiota (GM) modulates different
host pathways, playing a crucial role in human physiology and consequently impacting in the
development of some pathologic conditions. Explorations of how the microscopic communities
might contribute to health or disease have moved from obscure to ubiquitous. Recently, studies have
linked our microbial settlers to inflammatory bowel diseases (IBD)s, obesity, asthma, autism spectrum
disorders, stroke, diabetes, and cancer. In agreement with Hanage, who suggested a scepticism
dose about the predominant role of microbiota [1], we have edited this special issue with the aim to
publish manuscripts respecting this spirit of scientific rigor to the detriment of enthusiasm (which
often characterizes GM studies).
However, there is no doubt that microbial metabolites bridge various, even distant, areas of the
organism by way of the hormone and immune system, contributing to the development of different
pathologies, such as the autoimmune disorders, as discussed by Gianchecci et al. [2]. The impact of a
GM imbalanced in autoimmunity pathogenesis has been suggested by different experimental evidence,
and physiological mechanisms, (i.e., the establishment of immune homeostasis) are influenced by
commensal bacteria. Microbiota alterations generate effects in the immune system, such as intestinal
inflammation, enhanced gut permeability, and defective tolerance to food antigens. In particular,
early findings reported differences in the gut microbiome of subjects affected by several autoimmune
conditions, including prediabetes.
In addition, the microbiota seen also have implications in the therapeutic approaches of lymphoid
malignancies and immunotherapy-based cancer treatments. Zuccaro et al. [3], discussed the microbiota
impact during chemo-free treatment of lymphoid malignancies. To date, no studies have been
planned to evaluate the GM composition in patients with lymphoproliferative disorders (and treated
with chemo-free therapies), and the probable association between GM, treatment outcome, and
immune-related adverse events has never been analysed. The authors remark the necessity of
additional studies to make opportunities for a more personalized approach in the patients’ subset.
During the last few years, the GM has gained increasing attention as a consequence of its
immunomodulator role. In particular, with the introduction of checkpoint inhibitors’ immunotherapy
and adoptive cell transfer in oncology, these findings became of primary relevance in light of
experimental data that suggested microbiota involvement as a credible predictor of responsiveness.
These impacting themes have been discussed by Brandi et al. [4], who reviewed the GM implication in
anti-cancer immunotherapy strategies, remarking the need to identify the specific GM actions and
develop innovative strategies to favourably edit its composition.
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It is important to link microbiota alterations (dysbiosis) and intestinal-correlated diseases. In this
regard, the manuscript of Lopetuso et al. [5] is interesting, since it explores the role of bacteriocins
and bacteriophages in the most recurrent gastrointestinal disorders, speculating on their potential
therapeutic application. The bacteriocins are bactericidal peptides (produced by both gram+ and gram-
bacteria) with an inhibitory activity against diverse groups of undesirable microorganisms. Conversely,
the bacteriophages are viruses that are able to infect bacteria, forcing them to produce viral components.
Bacteriocins and bacteriophages can influence both human health and diseases because they modulate
the intestinal microbiota and regulate the relationships between different microorganisms, strains, and
cells living in the human gut.
However, one of the most important messages that this special issue conveys is that we are still far
from understanding the full extent of GM actions on human health and the impact of its manipulation.
Cianci et al. [6] systematically reviewed these advances, linking gut microbiota not only to colorectal
cancer, but also to oesophageal, stomach, and pancreatic cancer, and hepatocellular carcinoma. Hence,
the GM action appears to go beyond the direct effect on the intestines, reaching those districts that may
not be directly colonized by the various microbial species. This is crucially important when designing
new therapies, including surgery and radiotherapy, aiming to restore the damaged microbiome during
assessment of their impact on a patient’s health. This concept is extensively covered by Toor et al. [7] in
which the authors stressed their concerns on the impact of the microbiome on the uncontrolled use of
antibiotics (which is also a current major concern for the Public Health Authorities), chemotherapeutic
drugs, or even changes in dietary patterns. The authors not only summarized state-of-the-art strategies
to study gut microbiomes, but they also included new strategies to manage dysbiosis through diet, bile
acids, and immune pharmaceutics.
It is clear that one of the major concerns in the field is how immunotherapy may affect the
delicate equilibrium existing in the microbiome ecosystem, and vice versa. Picchianti–Diamanti et
al. [8] addressed this question in the context of rheumatoid arthritis (RA). In a pilot study, the authors
demonstrated that in addition to oral microbiota dysbiosis, gut dysbiosis was also detected. Hence,
the comparison of the impact of intestinal microbiota in three groups of RA patients and patients
receiving methotrexate and/or etanercept (a biotechnological agent targeting TNF-alpha) led the
authors to conclude that part of the benefits of this treatment is related to the partial restoration of the
beneficial microbiota.
However, the scenario gets more complex when considering the connections established by distant
organs, such as gut-associated lymphoid tissue (GALT, explained by Toor et al. [7]) or the gut-liver axis
reviewed by Milosevic et al. [9]. Milosevic et al. evaluated another GM aspect, the so called “gut-liver
axis”, which has attracted great attention in recent years. GM communication is bi-directional and
involves endocrine and immunological mechanisms. In this way, gut-dysbiosis and composition of
“ancient” microbiota could be linked to the pathogenesis of numerous chronic liver diseases, such
as chronic hepatitis B and C, alcoholic liver disease, development of liver cirrhosis, and finally the
hepatocellular carcinoma. The authors discussed the current evidence supporting a GM role in the
management of these different chronic liver diseases and potential novel therapeutic GM targets, such
as fecal microbiota transplants, antibiotics, and probiotics.
Detecting the microbial interactions is essential to understand the GM structure and function.
In a mouse model, Liu et al. [10] inferred the microbial co-occurrence patterns using a random matrix
theory-based approach in the GM in response to chondroitin sulfate disaccharide (CSD) under healthy
and stressed conditions. A total of 34 operational taxonomic units (OTU) were identified as module
hubs and connectors, likely acting as generalists in the microbial community. In particular, Mucispirillum
schaedleri acted as a connector in the stressed network in response to the CSD supplement and may play
a crucial role in bridging intimate interactions between the host and its microbiome. In addition, several
modules correlated with physiological parameters were detected. A positive correlation between
node connectivity of the proteobacteria with superoxide dismutase activities under stress suggested
that proteobacteria can be developed as a potential pathological marker. These results provided
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novel insights into GM interactions and may facilitate future endeavours in microbial community
engineering, directly influencing some molecular pathways.
The GM role is being extensively studied in the context of chronic inflammatory diseases,
in particular in inflammatory bowel diseases (IBDs), which have a multifactorial etiology (not firmly
established yet). The fact that IBD incidence is steadily increasing in developed and developing countries
clearly suggests that lifestyle changes are key players in the onset of these diseases. Many studies have
established that the GM biodiversity is frequently altered in IBD patients, in particular because of the
reduction in firmicutes and an increase in proteobacteria. In this situation, IBD patients are highly
vulnerable to any opportunistic pathogen, such as Candida (C) albicans, a serious clinical problem due
to the high associated morbidity and mortality. Consequently, the C. albicans infection complicates
the IBD treatment, as the anti-inflammatory compounds most commonly prescribed do not have
antifungal activity. With the aim to identify new compounds showing this dual effect, i.e., compound
having simultaneously antifungal and anti-inflammatory properties, Bortolus et al. [11] investigated
the antifungal properties of a novel compound, 2,3-dihydroxy-4-methoxybenzaldehyde (DHMB).
Using in vitro and in vivo models (murine DSS-induced colitis model), the authors demonstrated the
great potential this aromatic molecule has as an antifungal agent with anti-inflammatory properties.
On the other hand, Charlet et al. [12] investigated an alternative approach widely used in the
management of various inflammatory and autoimmune diseases: Immunotherapy with intravenous
immunoglobulin (IVIg). Using the same murine model, the authors demonstrate that this treatment has
a clear impact on GM composition, decreasing the content in Escherichia coli, Enterococcus faecalis, and
C. albicans populations. Conversely, the beneficial effects of IVIg were associated with the suppression of
inflammatory cytokine IL-6 and the enhancement of IL-10 and PPAR-gamma (involved in inflammation
resolution). Hence, it seems that the beneficial effects of IVIg in infectious diseases goes beyond a
simple neutralization of microbes, acting actively on anti-inflammatory pathways, which turned out to
be critical for protection against infection.
Importantly, all the basic concepts and general approaches developed while studying gut
microbiota may also apply, to a greater or lesser degree, to other biological systems. such as the
vaginal or skin ecosystems. This special issue contains a comprehensive review by Torcia [13] on the
interplay among vaginal microbiome, immune response, and sexually transmitted infections (STIs).
In addition to the role that the cervico-vaginal microbiota has during egg fertilization and pregnancy,
its maintenance is key in the prevention of infectious pathogens, particularly during the transmission of
the human immunodeficiency virus (HIV), the human papilloma virus (HPV), and the herpes simplex
virus 2 (HSV2). Furthermore, an increased risk of STI acquisition is clearly associated to vaginal
dysbiosis. Torcia [13] described the current knowledge on how the immune system, epithelial cells,
and microbiota are interconnected and discussed different prevention strategies. The latter has become
a worldwide health issue due to the high incidence of STIs in low- and middle-income countries and
due to their resurgence in developing countries.
Finally, Park et al. [14] discussed the GM role in the largest organ in the human body: The skin.
As in the gut, liver, or vagina, the pathological alteration of the microbiome system often leads to
inflammation. Interestingly, the authors described the opposite impact on the skin health of two
members of the same genus, Staphylococcus (S) aureus and S. epidermidis and they warn about the
importance of understanding how these two species can modulate the cutaneous-immune response
prior to manipulating their levels as part of a treatment. It is clear that this warning should be issued
for any microbiome ecosystem.
In other words, the different studies and data presented and discussed in this special issue
suggest the microbiota centrality in the development and maintenance of the “health” and in favouring
(those cases in which the microbiota’s complex relational architecture is dysregulated) the onset of
pathological conditions. The intricate relationships between the microbiota and human beings, which
invest core notions of biomedicine, such as “health” and “the individual,” concern not only problems
of an empirical nature, but seem to require the need to adopt new concepts and novel perspectives in
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order to be properly analysed and utilized, especially for their therapeutic implementation. In this
context, it is very adequate the contribution of Amedei et al. [15], which illuminates the discussion of the
theoretical proposals and innovations (from the ecological component to the notion of the polygenomic
organism) aimed at producing this perspective change. In conclusion, the authors analysed what
impact and what new challenges these novel approaches might have on personalized medicine.
Conflicts of Interest: The authors declare no conflict of interest.
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